Sera Prognostics (NASDAQ:SERA) Coverage Initiated by Analysts at Craig Hallum

Research analysts at Craig Hallum began coverage on shares of Sera Prognostics (NASDAQ:SERA) in a research report issued on Thursday. The firm set a “buy” rating and a $6.00 price target on the stock. Craig Hallum’s price objective would indicate a potential upside of 192.68% from the stock’s previous close.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Sera Prognostics in a report on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $5.50.

Sera Prognostics Trading Up 0.5%

Shares of NASDAQ SERA opened at $2.05 on Thursday. The stock has a market cap of $80.28 million, a P/E ratio of -3.15 and a beta of 0.94. Sera Prognostics has a twelve month low of $1.37 and a twelve month high of $4.09. The stock has a 50 day moving average of $2.01 and a two-hundred day moving average of $2.58.

Sera Prognostics (NASDAQ:SERA) last announced its earnings results on Wednesday, May 6th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.07 million. Sera Prognostics had a negative net margin of 56,385.97% and a negative return on equity of 41.02%. As a group, research analysts predict that Sera Prognostics will post -0.58 earnings per share for the current year.

Insiders Place Their Bets

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 22,639 shares of the company’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $1.90, for a total transaction of $43,014.10. Following the completion of the transaction, the chief executive officer owned 741,287 shares in the company, valued at approximately $1,408,445.30. This represents a 2.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have sold 51,133 shares of company stock valued at $99,174. Company insiders own 11.30% of the company’s stock.

Institutional Trading of Sera Prognostics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Squarepoint Ops LLC lifted its holdings in Sera Prognostics by 8.9% in the third quarter. Squarepoint Ops LLC now owns 93,063 shares of the company’s stock valued at $285,000 after acquiring an additional 7,643 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Sera Prognostics during the 4th quarter worth $31,000. Arkadios Wealth Advisors purchased a new position in shares of Sera Prognostics in the 1st quarter valued at about $25,000. Citadel Advisors LLC increased its holdings in shares of Sera Prognostics by 1.9% in the 3rd quarter. Citadel Advisors LLC now owns 653,746 shares of the company’s stock valued at $2,000,000 after purchasing an additional 12,439 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Sera Prognostics in the third quarter valued at about $38,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.